FDA Panel Thumbs Up for Teprotumumab for Thyroid Eye Disease

FDA panel unanimously recommends approval of teprotumumab for the treatment of active thyroid eye disease. 'I think we're finally going to be able to get a lot of people some help,' said one member.
Medscape Medical News

Full Story →